Cart
sales@molnova.com
hTYR/AbTYR-IN-1
CAS No. 1625821-37-5
hTYR/AbTYR-IN-1( —— )
Catalog No. M37018 CAS No. 1625821-37-5
hTYR/AbTYR-IN-1 is a dual hTYR/AbTYR inhibitor with inhibitory effects on hTYR and AbTYR, with IC50s of 5.4 μM and 3.52 μM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 34 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 101 | In Stock |
|
| 100MG | 151 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamehTYR/AbTYR-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionhTYR/AbTYR-IN-1 is a dual hTYR/AbTYR inhibitor with inhibitory effects on hTYR and AbTYR, with IC50s of 5.4 μM and 3.52 μM, respectively.
-
DescriptionhTYR/AbTYR-IN-1 (Compound 7) is a hTYR/AbTYR dual inhibitor, with IC50s of 5.4 μM and 3.52 μM for hTYR and AbTYR respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetTyrosinase
-
RecptorTyrosinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1625821-37-5
-
Formula Weight312.36
-
Molecular FormulaC18H20N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (400.18 mM; Ultrasonic )
-
SMILESC(=O)(C1=C(OC)C=CC=C1)N2CCN(CC2)C3=CC=C(O)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ricci F, et al. Computational methods to analyze and predict the binding mode of inhibitors targeting both human and mushroom tyrosinase. Eur J Med Chem. 2023 Aug 28;260:115771.?
molnova catalog
related products
-
Aloesin
Aloesin is a C-glycosylated chromone compound found in aloe (Liliaceae) that inhibits tyrosinase (IC50 = 0.9 mM) an enzyme responsible for catalyzing the first step of the conversion of tyrosine to melanin.
-
AMG 925
AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.
-
Flanvotumab
Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody targeting tyrosinase-related protein (TYRP1), exhibiting potent antitumor activity through natural killer-mediated and antibody-dependent cell-mediated cytotoxicity (ADCC).
